סך נכסי הפעילות העסקית ImmunoPrecise (IPA)

ImmunoPrecise Antibodies (IPA) is facing a liquidity shortage and a gradual depletion of resources due to R&D costs amid weak revenue. Business growth is being driven by AI services and licensing agreements for antibody discovery. This price chart on GURU.Markets, where total asset value stands at 37.92, confirms its status as a molecular biology leader implementing the LENSai platform for precise target analysis.

ImmunoPrecise Antibodies (IPA) balances operational risks and capital efficiency by integrating generative AI and the BioStrand antibody discovery platform, while an analysis of controlled resource changes on GURU.Markets, reverse-engineered via ROA, enables a real-time assessment of asset value and inflation resilience, distinguishing market leadership from dangerous overheating.